OCEAN BIOMEDICAL

Ocean Biomedical is a new-generation biopharma company that partners with leading scientists and research institutions to accelerate the translation of new discoveries into breakthrough medicines. We're working to bring together the interdisciplinary expertise and resources required to develop a diverse portfolio of pharmaceutical inventions and technologies through preclinical, clinical, and commercial development. We aim to build a continuous pipeline of drug development opportunities through our relationships with universities and medical centers. Our current product candidates consist of preclinical programs each with potential for broad application in oncology, fibrosis, and the treatment and prevention of severe malaria. Our programs in oncology and fibrosis are based on discoveries of disease pathways and related drug targets emerging from pioneering work in the field of chitinase biology by our scientific co-founder, Jack A. Elias, M.D., a pulmonary specialist who was formerly the Dean of Medicine at Brown, and the Chairman of Medicine at Yale. In infectious disease, we are developing both therapeutic and vaccine candidates against malaria, a disease that kills 500,000 children and infects 200-300 million people globally each year. Our malaria program is built on the discovery by Jonathan Kurtis, M.D., of two novel malaria antigens, PfSEA-1 and PfGARP which have shown a significant reduction in malaria parasites under multiple levels of in-vitro and animal model testing. (press links below). Kurtis is the Chairman of Pathology and Laboratory Medicine at Brown and the founding director of the Center for International Health Research.